Review
doi: 10.1007/BF02886737.
Human eosinophil heterogeneity
- PMID: 3544158
- DOI: 10.1007/BF02886737
Item in Clipboard
Review
Human eosinophil heterogeneity
Ric Clin Lab.
1986 Jul-Sep.
Abstract
The aim of this review is to examine some of the most important findings pointing toward human eosinophil heterogeneity. Special importance is given to cell density, surface receptors, metabolism and response to biological products or synthetic compounds.
Similar articles
-
The chemokine RANTES is more than a chemoattractant: characterization of its effect on human eosinophil oxidative metabolism and morphology in comparison with IL-5 and GM-CSF.J Invest Dermatol. 1994 Jun;102(6):906-14. doi: 10.1111/1523-1747.ep12383399. J Invest Dermatol. 1994. PMID: 7516398
-
IL-16 activates plasminogen-plasmin system and promotes human eosinophil migration into extracellular matrix via CCR3-chemokine-mediated signaling and by modulating CD4 eosinophil expression.J Immunol. 2004 Oct 1;173(7):4417-24. doi: 10.4049/jimmunol.173.7.4417. J Immunol. 2004. PMID: 15383572
-
The synthetic PPARgamma agonist troglitazone inhibits IL-5-induced CD69 upregulation and eosinophil-derived neurotoxin release from eosinophils.Pharmacology. 2005 Jul;74(4):169-73. doi: 10.1159/000085034. Epub 2005 Apr 7. Pharmacology. 2005. PMID: 15818060
-
The eosinophil.Annu Rev Immunol. 2006;24:147-74. doi: 10.1146/annurev.immunol.24.021605.090720. Annu Rev Immunol. 2006. PMID: 16551246 Review.
-
Regulation of eosinophil development and survival.Curr Opin Hematol. 2017 Jan;24(1):9-15. doi: 10.1097/MOH.0000000000000293. Curr Opin Hematol. 2017. PMID: 27673511 Review.